Galimedix is led by pharma industry veterans - the key members of the proven neuropharmaceutical team who developed and commercialized the blockbuster Alzheimer´s drug Namenda (Memantine). These experts, who led the development of GAL-101 and GAL-201 for 7 years at Merz Pharma, are now leading those efforts at Galimedix, to become an innovator of therapies in neurodegenerative diseases.
Andrew Pearlman, Ph.D.
Dr. Andrew Pearlman has more than 35 years’ experience founding and managing US/Israel biotechnology and medical device companies. A biophysicist, Dr. Pearlman has invented, licensed, developed and managed medical devices and biotechnologies from business and product concept through technology development, IP, prototyping, clinical trials, regulatory approval, manufacturing, and product sales. Dr. Pearlman has raised more than $120mm for new biomedical ventures he founded in Israel, including Medgenics, a gene therapy company he took from laboratory research stage through Phase 2 clinical trials and through IPOs on both the London Stock Exchange and the NYSE, building it to over $350 million in market cap. In less than one year, Dr. Pearlman founded Galimedix, built a world class team, and successfully completed a seed round of financing. Dr. Pearlman holds a Ph.D. in Biophysics from the University of California at Berkley (doctoral thesis under Nobel Laureates - Professors Melvin Calvin and Donald Glaser).
Hermann Russ, M.D. Ph.D.
Co-Founder, Chief Scientific Officer
Hermann Russ is a board-certified clinical neurologist, a board-certified experimental pharmacologist and a pharmacist. He is a co-founder of Galimedix. Dr. Russ is the inventor of the use of former Alzheimer-targeting molecule GAL-101 (MRZ-99030) in the treatment of degenerative diseases in the retina including glaucoma and dry macular degeneration. He is also co-inventor of the so-called "trigger effect" of GAL-101 and GAL 201, which is a unique reverse prion-like self-propagation mechanism of action important for the clinical treatment regimen. Dr. Russ championed these assets when they were being developed by Merz beginning in 2007.
He holds a Ph.D. in neuro- and bio-chemistry from the University of Wurzburg, Germany. During his academic career (until 1999) at the universities of Wurzburg, Regensburg and Giessen he had different positions and functions including consultant of clinical neurology and professor of pharmacology. His scientific focus is on neurodegenerative diseases, including Alzheimer's, Parkinson`s, and degenerative retina diseases. He is (co)inventor of around 25 patents and (co)authors of around 50 peer-reviewed scientific publications.
Dr. Russ has 20 years of Pharma industry experience. Prior to joining Galimedix he was vice president of Neuroscience Project Leadership in Specialty R&D of Teva Pharmaceuticals International GmbH (TPIG) Switzerland. His responsibilities included the strategic leadership and management of "project champions" of all global cross-functional drug development programs in the area CNS and pain throughout all phases. He also served on the Swiss Board of TPIG as Managing Officer. Prior to that he worked for 8 years at Merz Pharma as Head of Global R&D CNS leading a R&D organization in the indication areas neurology and psychiatry, spanning from early discovery to clinical development and regulatory submission. That included management of five R&D departments. From 1999 to 2007 Dr. Russ was with Merck KGaA as Head of the Medical Center of Excellence CNS (last position).
Phyllis K. Bellin, M.B.A.
Board Member, Chief Financial Officer
Ms. Bellin has more than 30 years' experience in founding and leading technology-based companies. Before joining Galimedix, she served as Vice President Finance & Administration, Corporate Secretary and Treasurer at Medgenics, Inc., leading IPOs on the London AIM and the NYSE. Previously, she was an officer at Citibank in Corporate Lending and Strategic Planning. Since moving to Israel in 1980, Ms. Bellin managed finance and administration for a number of early stage high-tech ventures in automotive safety, and health care. She was also Founder and Vice President of Gintec Active Safety Limited and responsible for finance and administration of its subsidiaries including RoadEye Limited. She served on the Board of Directors of the Misgav Economic Corporation and private companies in Israel and the Netherlands. Ms. Bellin earned her MBA in Finance and Accounting from Columbia University, an MAT from the University of Chicago and a BA from Clark University.
Yaniv Barkana, M.D.
Chief Medical Officer
Dr. Barkana is a Past-President of the Israel Glaucoma Society and Senior Ophthalmologist, Surgeon and head of Tele-glaucoma service at the Baruch Padeh-Poriya Medical Center Department of Ophthalmology. Until recently he has been in the glaucoma service of the Assaf Harofe Medical Center, and a Senior Clinical Lecturer at the Tel Aviv University Faculty of Medicine. He received his M.D. from the Hebrew University in Jerusalem, completed his residency in Ophthalmology at the Assaf Harofe Medical Center and his clinical fellowship in glaucoma at the New York Eye and Ear Infirmary.
Chris Parsons. Ph.D., P.D.
Co-Founder, Chief Pharmacologist and VP of Non-Clinical Development
Chris Parsons is a British neuropharmacologist / electrophysiologist. He is a co-inventor of the so-called “trigger effect” of GAL-101 and GAL-201, which is a unique positive, reverse prion-like self-propagation mechanism of action important for the clinical treatment regimen. Dr. Parsons has an extensive history with the two Galimedix assets when they were being developed by Merz beginning in 2007.
With more than 26 years of pharmaceutical industry experience, he served as “principle scientific expert – pharmacology” for Merz Pharma in Frankfurt, Germany just prior to joining Galimedix. His previous responsibilities included leading the department of in vitro pharmacology at Merz with nine full time employees.
His main responsibility at Merz was for early in vitro drug discovery / drug profiling. He was the preclinical champion for the profiling of memantine (50 full papers / reviews) and was also deeply involved in the discovery / profiling of novel lead molecules such as neramexane and other compounds such as mGluR5 NAMs / PAMs and GAL-101 and GAL-201. Additionally, he was the project manager for four internal projects (one ion channel, one protein aggregation and two most recent ones on adipose tissue biology). He was directly responsible for co-ordination of fruitful collaborations with several hundred external CROs and academic partners.
He holds a Ph.D. in neuropharmacology from the University of London (RVC), U.K. and is a “Privat Dozent”/lecturer at the University of Tübingen in Germany. During his academic career at the universities of Swansea, London, Bristol and the MPI in Munich, he held various postdoctoral positions. His main scientific focus for three decades has been neurodegenerative diseases, including Alzheimer’s and degenerative retinal diseases. He is the inventor or co-inventor of 28 patents and author or co-author of 115 peer-reviewed scientific publications as well being a co-author of more than 210 abstracts for scientific conferences.
Dr. Parsons is also a senior editor for the journal Neuropharmacology.